Assertio Therapeutics Investor Presentation — November 2017

Document content

Third Quarter 2017 Financial Update

November 7, 2017Forward Looking Statements

2The statements that arenothistorical facts contained inthispresentation areforward -looking statements that involve risks and

uncertainties including, butnotlimited to,those related toDepomed’s strategy, plans, objectives, expectations (financial orotherwise)

and intentions, future financial results and growth potential, including projected revenues and earnings, expectations regarding

periods ofexclusivity fortheNucynta®franchise, Gralise®,CAMBIA®,Lazanda®,Zipsor®,cebranopadol ,aswell asany other

statements that arenothistorical facts .These forward -looking statements arebased onDepomed’s current expectations and

inherently involve significant risks anduncertainties .

Actual results andthetiming ofevents could differ materially from those anticipated insuch forward -looking statements asaresult of

these risks anduncertainties, which include, without limitation :risks associated with thecommercialization ofourproducts, including

competitive risks;risks relating tothepending ANDA litigation forNucynta and Nucynta ER;pricing and third party payor

reimbursement risks forourproducts ;regulatory risks, including FDA regulation ofourproducts andregulation ofourpromotional

practices ;risks relating tothesuccessful development ofnew product candidates ;aswell asother risks related toDepomed's

business detailed from time-to-time under thecaption "Risk Factors" andelsewhere inDepomed's SEC filings andreports, including

initsAnnual Report onForm 10-Kfortheyear ended December 31,2016 anditsmost recent Quarterly Report onForm 10-Q.

Depomed undertakes noduty orobligation toupdate anyforward -looking statements contained inthispresentation asaresult ofnew

information, future events orchanges initsexpectations except asmay berequired bylaw.

This presentation contains non-GAAP financial measures, including EBITDA, Adjusted EBITDA andother financial measures labeled

as“non-GAAP .”Please refer toDepomed’s November 7,2017 earnings release ontheDepomed website (Depomed .com) foran

explanation ofthese non-GAAP financial measures andfortables thatreconcile thenon-GAAP figures totheir GAAP equivalent .“Safe Harbor” Statement Under the Private Securities Litigation Reform Act of 1995A Clear Strategy for Growth

Not One But Three Pillars Form Our Strategy

Pain Businesses BUILD

Principles Guiding the Way We Do Business

Across the BusinessPROFITABILITY

4Maintain aStrong NUCYNTA Franchise

•NUCYNTA ER outperformed the market by 640 bps in Q3 20171